WEST Staff & Board of Directors


Director of Operations

Jaime Luna joined WEST in 2012 and serves as Director of Operations. She comes to WEST with extensive experience in nonprofit organizations, specifically in program operations and project management. Jaime served as Director of Program Operations for Illumination Foundation working with homeless families and individuals. As a key member, she helped the grassroots nonprofit grow from its infancy to a $2,000,000 organization in three short years. Previous to Illumination Foundation, Jaime worked at the YMCA of Metropolitan Los Angeles, Camping Services. She filled in the role of Operations Executive Director. She oversaw the operation of many YMCA camps and developed, monitored, and managed related annual operating budgets of over $2,000,000, including human resources, office administration, accounts receivable, accounts payable, payroll, and procurement. Jaime completed her Master's degree in Education. 

Board of Directors

President: Jo Viney, Ph.D., is Co-Founder and CSO of Pandion Therapeutics, a start-up biotech company focused on drug discovery in autoimmunity, inflammation and transplant. Previously Jo worked at Biogen where she began as VP, Immunology Research and was responsible for building the company’s immunology portfolio before moving on to become SVP, Drug Discovery. Before moving to the East Coast, Jo worked at Genentech, Immunex and Amgen, but she originally hails from the UK where she received her PhD from the University of London. Throughout her career, Jo has been passionate about workplace inclusiveness, promoting the careers of women and under-represented minorities in science. She is involved with several groups driving this mission, and joined the Board of WEST in 2015 and is currently serving as President. Jo is also a member of the Board of Directors for CaroGen Corp, and is a member of the Scientific Advisory Board for Vaxart Inc. 

Vice President: Mariana Nacht, Ph.D., is currently VP Cancer Biology, KDAc Therapeutics, Cambridge with 19 years of experience in biotechnology. Prior to Torus, she was VP and Head of Biology at Padlock Therapeutics and one of the first employees at Avila Therapeutics and directed the biology team. Avila was a start-up biotech company dedicated to discovering and developing irreversible small molecule inhibitors of kinases and proteases for oncology and infectious diseases. During those 5 years, three drug candidates were discovered, and two were advanced to clinical trials (the BTK inhibitor CC-292, and the mutant selective EGFR inhibitor CO-1686, partnered with Clovis Oncology). After the acquisition of Avila by Celgene in 2012, Mariana continued to lead biology research at Celgene Avilomics Research before joining Padlock as an early member of the executive team. Mariana started her biotech career at Genzyme, where she worked for ten years, focusing on various aspects of human oncology including the study of proteins that promote or prevent tumor angiogenesis and growth. Mariana received her B.S. in Biology from Tufts University and a Ph.D. from the University of Pennsylvania. She continued her training as a post-doctoral fellow in the laboratory of Tyler Jacks at MIT before continuing her career in industry.

Previous Chair: Alexandra (Sandra) Glucksmann, Ph.D., was most recently Chief Operating Officer at Editas Medicine Inc., a gene editing company whose mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of genetic diseases. Alexandra was most recently Senior Vice President of Research and Development at Cerulean Pharma, which she joined at its founding. Cerulean Pharma is a clinical-stage company developing innovative nanopharmaceutical tumor-targeting products. She was brought in by founders and investors to help build Tempo (renamed Cerulean) from the ground up. She was a key contributor to all aspects of building the company including setting the strategy, analyzing product development opportunities, cultivating platform and product partnership prospects and participating in fundraising activities. Prior to joining Cerulean in 2006, she spent 13 years at Millennium Pharmaceuticals which she joined in 1993 as one of its first scientists. At Millennium, she held a series of positions with increasing responsibility, ultimately becoming Vice President of all platform technology groups before moving into a senior role in strategic program management and operations. In this role, she worked closely with the CEO and led company-wide process improvement initiatives and participated in business development and M&A efforts. During her tenure at Millennium, Alexandra was critical in helping Millennium evolve from a genomics research-focused organization to a fully integrated and commercial pharmaceuticals company.  Her division played an integral role in the numerous Millennium-large pharma collaborations, which generated over $1.8 billion in funding for the company. She serves on the Board of Directors of Taconic Farms and is the Chair of the Board of Women in the Enterprise of Science and Technology (WEST). She is also a member of the Advisory Council of the Harvard Partners Center for Personalized Genetic Medicine. Alexandra was a post-doctoral fellow at the Massachusetts Institute of Technology and holds a Ph.D. with honors from the University of Chicago.

Board Members:

Chesley Chen is Chief Executive Officer of Safety Partners, Inc., which provides environmental, health, and safety programs to over 200 life science and technology companies each year. He is a serial entrepreneur with over 30 years experience in launching, scaling, and reinventing businesses in healthcare, life sciences, high tech, and financial services with firms which include Health Dialog, Good Measures, Goldman Sachs, The Warner Babcock Institute for Green Chemistry, and Hughes Aircraft Company. Chesley holds a BS in Civil Engineering from Tufts University, an SM in Aeronautics and Astronautics from MIT, and an MBA from the Harvard Business School. In addition to the Board of WEST, he serves on the Advisory Board of the Harvard Medical School – Chinese Scholars and Students Association. He dedicates his time to mentoring new and experienced entrepreneurs through storytelling and learnings gathered along his journey. He is a devoted family man, rock climber, and karate-ka.

Jodi Detjen is a clinical professor of management at Suffolk University and is the MBA program director. She co-authored The Orange Line: A Woman’s Guide to Integrating Career, Family and Life in May 2013. She focuses on consulting and leadership development on these principles in her consulting firm, Orange Grove Consulting. Her vision is to help organizations globally achieve gender parity in leadership. Jodi has been consulting around leadership and organizational effectiveness for over 25 years. She teaches, consults and writes in areas of leadership development, managing change, increasing impact, and how women can realize their power. Jodi teaches management at the MBA, Undergraduate and Executive Education levels online, in the classroom and internationally. Prior to teaching Jodi was an international management consultant based in London, England working with Global 1000 clients. Jodi focused on redesigning operations thereby realizing significant financial benefits. Her MA in International Development Policy is from Duke University and her B.Sc., from Virginia Tech in Management Science. 

Ann DeWitt is a Senior Director of Business Development & Licensing at Sanofi. She joined Sanofi in 2013 as a team member of Sanofi Ventures, leading early-stage equity investments. Prior to Sanofi, Ann was Senior Director, Corporate Development at Permeon Biologics, a Flagship Venture’s co-founded company. Previously, she was a Senior Associate at Flagship Ventures, an early stage venture capital firm with $1.7 billion under management and was a Board observer for several portfolio companies. Post-doctorate, she worked at 3M Company in corporate research and in businesses, including 3M Pharmaceuticals, and was a Technical Circle of Excellence Award winner. Ann is a long-time member of the Life Sciences Council of Springboard Enterprises, an organization dedicated to building high-growth technology-oriented companies led by women. Ann holds a B.S. from the University of Illinois in engineering, a Ph.D. from MIT in systems biology, and an M.B.A. from Harvard Business School.

Alison Elworthy is the VP of Operations and Chief of Staff at HubSpot, where she is responsible for HubSpot's operating system, strategic planning and execution, and ultimately, keeping the company on track as the world's leading inbound marketing and sales platform. Prior to her role as VP and Chief of Staff, Alison led various functions at HubSpot as Marketing Operations Manager, Sales Operations Senior Manager, and Director of Operations. She was previously a User Experience Specialist at Fidelity Investments, focused on the customer experience of their business and customer facing products and websites. Outside of work, she is a wine and food enthusiast and mom to her 2 year old son and newborn daughter. She holds a BS in Human Factors Engineering from Tufts University and an MBA from the Tuck School of Business at Dartmouth.

Natasha Engan is the SVP of Global Consulting at Deltek. Prior to that, she was Vice President of IBM Security Financial Services Market. Her responsibilities included business ownership for the security services and security software within the Financial Services Market. Prior to this position, Ms. Engan was the Vice President of Security Services, IBM Security North America.  In this role Ms. Engan had general management responsibility for IBM's Security Services businesses including strategy, P&L management, direct and indirect sales, delivery, and client satisfaction. Ms. Engan has held a number of other leadership roles including the Vice President of IBM Cloud Services in North America.  In this role, Ms. Engan had responsibility for the overall executive management of IBM's cloud services businesses including strategy, market selection, day-to-day sales, P&L management, partner strategy and customer satisfaction.  She also served as the Vice President of IBM Global Services, Solutions Sales, for the Western United States. In that capacity Ms. Engan led IBM ITS's sales initiatives around IT Strategy and Design, Data Center Services, Integrations Communications, End User support, Business Continuity and Resiliency, Security, and Mobility service offerings. Ms. Engan joined IBM in 2005 via the Ascential Software acquisition.  She has a strong transactional software and Saas background with experience in product marketing, managing both services sales and delivery teams, implementing global delivery models worldwide, and working as a regional services leader in Asia Pacific. Natasha holds a BA from Mount Holyoke College in Chemistry and Environmental Science and completed the Executive Program at Louisiana State University. She resides with her and two children in the Boston Area.

Meredith Fisher, PhD is a Partner at the Partners Innovation Fund- the venture arm of Partners Healthcare System in Boston, MA. Previously, she was in the private office at Bracebridge Capital serving as Director of Private Investments where she led investments in early stage life science companies. Prior to that role she led business development for Ginkgo BioWorks- an MIT spin out- and was Senior Director of Technology and Business Development of Enlight Biosciences- a venture creation company founded by PureTech Ventures. She spent several years working as a scientist in drug discovery and assay development for Idenix Pharmaceuticals and Anadys Pharmaceuticals (formerly, Scriptgen). Meredith received her undergraduate degree from Mount Holyoke College, her MBA from the MIT Sloan School of Management and her PhD in molecular microbiology from Harvard University. 

Debbie Gustafson is the CEO of Energetiq Technology, Inc., a high tech equipment company. Debbie is a hands-on executive and leader with a proven track record of organizational success in the semiconductor and related industries. She is an expert in operations and sales & marketing. She has vast international experience including Asia, Europe, and Israel and is experienced in negotiating large, complex and multifaceted contracts and supplier agreements. In a prior role she has opened up offices and joint ventures in Japan and Korea.  She has held strategic marketing and sales positions at Mykrolis (Entegris), ASTeX (MKS), Teradyne and Helix (Brooks Automation). She holds a BS in Mechanical Engineering from Southeastern Massachusetts University (UMass Dartmouth) and an MBA in Management from Bentley University. 

Danielle Lauzon is a partner in Goodwin Procter LLP’s Technology Companies & Life Sciences Group. Danielle’s representation of start-up and later stage companies spans the entire corporate life cycle, including formation matters, general corporate representation and counseling, venture capital financings, public offerings and mergers and acquisitions. Her clients are in the life sciences, software and healthcare information technology services industries. Prior to joining Goodwin Procter in 2005, Danielle was an associate in the Business Practice Group at Testa, Hurwitz & Thibeault in Boston. Danielle is a member of the Massachusetts and Boston Bar Associations. Danielle holds a J.D. from Villanova University School of Law (magna cum laude, Order of the Coif) and a B.A. from the University of Michigan.

Mary Ann O’Loughlin is Regional Corporate Relations Director in Executive Education at Harvard Business School (HBS) where she leads the team supporting corporate clients in Europe, the Middle East, and Africa. Her global business career has spanned sales, marketing, consulting, and senior management roles in large corporations and small start-ups. She has lived and worked in Canada, France, the United States, and the United Kingdom. Prior to joining HBS in 2007, Mary Ann spent ten years with the UK research and consulting company Ovum in both London and Boston. In addition to her own work as a telecoms sector Principal Consultant, she managed Ovum’s US operation as President of Ovum North America for five years. Previously, Mary Ann had founded and managed a consulting and telecoms service company in France and, earlier in her career, she worked for IBM Canada, Hewlett Packard and Alcatel in senior sales and product marketing positions. Mary Ann holds a BS in Physics from McMaster University (Ontario), an MS in Biophysics from the University of Toronto, an MBA from Insead, and a graduate certificate in Executive Coaching from the William James College. A UK native, Mary Ann lives in Boston. She is a fluent French speaker.

Jen Zarutskie Sieczkiewicz (Treasurer/Clerk) is Associate General Counsel, Corporate at Biogen, Inc., where she counsels the Business Development unit on the legal implications of transaction initiatives and strategies. She also serves as lead asset team counsel for several programs, advising on matters relating to clinical trials, program management, contract interpretation, regulatory approval and exclusivity, labeling, global commercial strategy and R&D and clinical compliance regulations. Prior to moving to Biogen, she was Director of IP at Dyax Corp and also spent time in firm practice, most recently at Foley Hoag LLP, as a patent attorney. Jen also served on the Board of the Boston Patent Law Association as well as a Committee Chair for several years. Jen received her J.D. from Boston University Law School, her Ph.D., in Biological Chemistry from MIT, and her A.B. in Chemistry from Bryn Mawr College.

Shelia Violette, Ph.D. is currently an Entrepreneur in Residence at Atlas Venture, Cambridge, MA.  She has more than 20 years of industry experience advancing programs from early research to clinical development.  Shelia has provided strategic and operational leadership to multi-disciplinary teams of scientists, led several research and early clinical programs, and authored more than 80 manuscripts and patents. She was previously Vice President of Tissue Injury and Fibrosis Research at Biogen and prior to that Vice President of Research at Stromedix. Shelia has directed research and led therapeutic programs at several biotechnology companies including Repligen, Ariad, Stromedix and Biogen. She received her Ph.D. in Pharmacology from Yale University and carried out her post-doctoral training with Frank Ruddle in the Department of Biology at Yale University.

Chair Emeritus

Janice Bourque is former Senior Vice President and Group Head-Life Sciences for Comerica Bank where she was responsible for leading Comerica’s national strategy for the life sciences. Prior to that, Ms. Bourque was President/CEO of the Massachusetts Biotechnology Council (MBC) where she led the organization for 12 years. In 2004, she was awarded the Woman of Valor Award by the American Diabetes Association and the 2004 Distinguished Leadership Award by the Huntington Disease Society for her work in public policy and public health. In 2003, Boston Magazine named her one of Boston’s 100 most influential women and the Cambridge Chamber Commerce awarded her Business Person of the Year. Ms. Bourque received her MBA degree in finance and accounting and her BS degree in veterinary science from the University of New Hampshire. 

Board Emeritus

Abigail Barrow, Ph.D., is the Interim Executive Director, Office of Technology Commercialization and Ventures (OTCV) at the University of Massachusetts.  She joined the UMass President’s Office in 2004 as the Founding Director of the Massachusetts Technology Transfer Center (MTTC) which is housed in OTCV. At OTCV she supports the campus technology transfer programs as well as assisting with start-up formation and other systemwide entrepreneurship activities at UMass. She is also responsible for the overall management of the MTTC and the development of its programs. Prior to joining UMass, Dr. Barrow served as managing director of William J. von Liebig Center at the University of California San Diego (UCSD). Dr. Barrow worked in a variety of roles at UCSD CONNECT from 1990 to 2001. Dr. Barrow is on the board and is Chair of VentureWell. Dr. Barrow received her Ph.D. from the Science Studies Unit and a B.Sc. in Mechanical Engineering from the University of Edinburgh.



Joel MacAuslan, Ph.D., is Chief Executive and Chief Science Officer of STAR Analytical Services, which provides mathematical and analytical capability for clients' innovation projects that require expertise in system modeling, signal processing, and nonlinear dynamics - from brain surgery to rocket science. He founded STAR on an NIH grant to apply techniques of chaos theory to the dynamics of the larynx. Joel has participated actively in WEST since early 2000. Joel holds a Ph.D. in Astrophysics from Cornell and has spent over twenty-five years in mathematical speech, signal, and image-processing analysis.